GWM
CTMX icon

Geneos Wealth Management’s CytomX Therapeutics CTMX Stock Holding History

Geneos Wealth Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,650
Closed -$10K – 2571
2020
Q1 		$10K Hold
1,650
– – ﹤0.01% 1810
2019
Q4 		$14K Buy
+1,650
New +$11.1K ﹤0.01% 1828

Other funds holding CTMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geneos Wealth Management's CTMX Position: Q2 2020 in Review

Geneos Wealth Management sold out of CytomX Therapeutics (CTMX) in Q2 2020, closing a stake of 1,650 shares — an estimated $10K sold.

Geneos Wealth Management first reported a position in CTMX in Q4 2019 and held it in 2 quarters. The position peaked at $14K in Q4 2019. 134 funds tracked by Wall St. Rank hold CTMX as of Q2 2020.

  • Geneos Wealth Management reported no remaining CytomX Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Geneos Wealth Management sold 1,650 CytomX Therapeutics shares in Q2 2020, an estimated $10K.
  • Geneos Wealth Management first reported a position in CytomX Therapeutics in Q4 2019 and held it in 2 quarters.
  • Geneos Wealth Management's CytomX Therapeutics position peaked at $14K in Q4 2019.
  • 134 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2020.

Based on Geneos Wealth Management's 13F filing for Q2 2020, filed 7 Sep 2021.